Printer Friendly

DNAVEC obtains United States patent.

DNAVEC Research, Inc. (Ibaraki, Japan) has patented a recombinant Sendai virus vector for introducing exogenous genes to airway epithelia and a method for introducing exogenous genes using the vector. The recombinant Sendai virus vector enables efficient gene transfer to native mucus-layered airway epithelial cells by briefly contacting the vector with the cells. Furthermore, the vector can introduce genes to not only apical surfaces but also submucosal glands where CFTR primarily expresses. The vector can thus be used for gene therapy of CF, a CFTR-deficient disease. (US 7,314,614)
COPYRIGHT 2007 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Date:Nov 1, 2007
Words:89
Previous Article:InterMune buys out license agreement for pirfenidone.
Next Article:Innogenetics obtains United States patent.
Topics:


Related Articles
MorphoSys widens scope of United States patent for HuCAL technology.
Federal Court of Appeals to decide on claims for United States in fraud case against Hoffmann-La Roche.
The "Hatch" factor: is intellectual property reform on the horizon?
Eisai, DNAVEC Join in Drug Discovery Research for Alzheimer's Disease.
Forest and Merz File Additional Lawsuit Against Several Companies for Patent Infringement.
DNAVEC obtains United States patent.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters